KCM
IMNM icon

Kennedy Capital Management’s Immunome IMNM Stock Holding History

Kennedy Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.28M Buy
287,030
+675
+0.2% +$15K 0.13% 242
2025
Q4 		$6.15M Buy
286,355
+28,929
+11% +$508K 0.13% 254
2025
Q3 		$3.01M Buy
257,426
+148,074
+135% +$1.47M 0.07% 381
2025
Q2 		$1.02M Buy
109,352
+94,627
+643% +$776K 0.02% 505
2025
Q1 		$99.1K Buy
14,725
+204
+1% +$1.96K ﹤0.01% 636
2024
Q4 		$154K Buy
+14,521
New +$175K ﹤0.01% 664

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Kennedy Capital Management's IMNM Position: Q1 2026 in Review

Kennedy Capital Management increased its Immunome (IMNM) stake by 0.24% in Q1 2026, buying an estimated $15K and bringing the position to 287,030 shares worth $6.28M. The position accounts for 0.13% of the portfolio, ranked #242.

Kennedy Capital Management first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Kennedy Capital Management held 287,030 shares of Immunome worth $6.28M as of Q1 2026.
  • Kennedy Capital Management bought 675 Immunome shares in Q1 2026, an estimated $15K.
  • Immunome made up 0.13% of Kennedy Capital Management's portfolio in Q1 2026, its #242 holding.
  • Kennedy Capital Management first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.